Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.

Daisuke YabeAtsutaka YasuiLinong JiMoon Kyu Lee Ronald Ching-Wan Ma Tien-Jyun ChangTomoo OkamuraCordula ZellerStefan KaspersJisoo LeeSven KohlerYutaka Seino

Published in: Journal of diabetes investigation (2018)

In the present pooled analysis, EMPA was well tolerated in East Asian type 2 diabetes patients based on >2,100 patient-years' exposure, consistent with results from the overall analysis population.

Keyphrases

type diabetes
clinical trial
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
open label
cardiovascular disease
randomized controlled trial
phase iii
adipose tissue
phase ii